Key Drivers
- High margins
- Strong FCF
- Intangible risk
AIAI Summary
The Breathe Right acquisition shifts Prestige from a steady consolidator to an M&A-driven, leverage-sensitive growth story—investors should now judge upside primarily on timely integration synergies, near-term EBITDA/margin stabilization, and the company's ability to restore cash/covenant headroom rather than on organic margin resilience alone. Action: require evidence of revenue lift or margin accretion from Breathe Right within 12–18 months, monitor cash on hand, covenant metrics, and any goodwill/impairment indicators each quarter; absent that, downside risk from leverage and intangible writedowns is material.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Strong FCF
- •Intangible risk
PBH demonstrates strong FY profitability and FCF generation with healthy liquidity and manageable leverage, but its value is concentrated in large intangibles and quarterly cash/earnings volatility raises impairment and short-term liquidity risks.
Price Behavior
Key Price Behavior Insights:
- •Below last-month SMA
- •Oversold momentum
- •Low-$60s support
PBH is trading below its last-month SMA (~$65.9) with an oversold RSI (~22) and firm support in the low-$60s (~$60.06–$60.75) but faces resistance into $66–$70 and risks further downside if that support breaks.
Sharp decline from highs near $69–$70 into the low-$60s over late
Sentiment & News
Key News Insights:
- •Prestige acquisition
- •Institutional stake
- •Premium resilience
Prestige (NYSE: PBH) agreed to buy Breathe Right for $1.045B and drew a new institutional stake, while Premium Brands (TSE: PBH) reported solid FY25 sales and margin recovery despite severe commodity inflation. #M&A
Prestige's deal and fresh institutional interest should bolster its share outlook via M&A-driven growth expectations, while Premium's improving margins signal operational resilience amid inflation, though the shared “PBH” ticker across exchanges may cause short-term investor confusion
Similar Companies in Healthcare
Other companies in the same sector with AI ratings